X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA GSK PHARMA PLETHICO PHARMA/
GSK PHARMA
 
P/E (TTM) x -1.1 59.8 - View Chart
P/BV x 0.0 12.0 0.1% View Chart
Dividend Yield % 0.0 2.4 -  

Financials

 PLETHICO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
GSK PHARMA
Mar-18
PLETHICO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3952,760 14.3%   
Low Rs312,040 1.5%   
Sales per share (Unadj.) Rs604.4339.0 178.3%  
Earnings per share (Unadj.) Rs32.541.4 78.4%  
Cash flow per share (Unadj.) Rs51.345.9 111.8%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs473.6242.9 195.0%  
Shares outstanding (eoy) m34.0884.70 40.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.47.1 5.0%   
Avg P/E ratio x6.657.9 11.3%  
P/CF ratio (eoy) x4.252.3 7.9%  
Price / Book Value ratio x0.59.9 4.6%  
Dividend payout %084.5 0.0%   
Avg Mkt Cap Rs m7,262203,280 3.6%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5965,234 30.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,59828,715 71.7%  
Other income Rs m386545 70.8%   
Total revenues Rs m20,98429,260 71.7%   
Gross profit Rs m2,8185,059 55.7%  
Depreciation Rs m642380 169.0%   
Interest Rs m1,5932 79,660.0%   
Profit before tax Rs m9695,222 18.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m-1381,892 -7.3%   
Profit after tax Rs m1,1073,508 31.6%  
Gross profit margin %13.717.6 77.6%  
Effective tax rate %-14.336.2 -39.4%   
Net profit margin %5.412.2 44.0%  
BALANCE SHEET DATA
Current assets Rs m18,87721,815 86.5%   
Current liabilities Rs m11,89615,999 74.4%   
Net working cap to sales %33.920.3 167.3%  
Current ratio x1.61.4 116.4%  
Inventory Days Days3664 56.5%  
Debtors Days Days19819 1,058.7%  
Net fixed assets Rs m9,86112,475 79.0%   
Share capital Rs m341847 40.2%   
"Free" reserves Rs m12,33119,726 62.5%   
Net worth Rs m16,13920,573 78.4%   
Long term debt Rs m4,7066 78,430.0%   
Total assets Rs m33,14639,475 84.0%  
Interest coverage x1.62,612.0 0.1%   
Debt to equity ratio x0.30 99,981.6%  
Sales to assets ratio x0.60.7 85.4%   
Return on assets %8.18.9 91.6%  
Return on equity %6.917.1 40.2%  
Return on capital %12.326.2 46.8%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,402564 780.6%   
Fx outflow Rs m3,1847,429 42.9%   
Net fx Rs m1,219-6,865 -17.7%   
CASH FLOW
From Operations Rs m2,4374,728 51.6%  
From Investments Rs m-6,265-1,042 601.3%  
From Financial Activity Rs m2,490-3,066 -81.2%  
Net Cashflow Rs m-1,337620 -215.8%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 4.3 10.2 42.2%  
FIIs % 5.5 23.8 23.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 15.4 48.7%  
Shareholders   10,665 102,036 10.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS